Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Nuvation conducts phase I/II study of NUV-422 in recurrent or refractory high-grade gliomas

Dec. 9, 2020

New vulnerability in "KL" KRAS subtype

Dec. 7, 2020

Data from phase II studies of VAL-083 in glioblastoma

Dec. 7, 2020

New IDO-1 inhibitors synthesized at Hutchison MediPharma

Dec. 7, 2020

Jiangsu Hansoh Pharmaceutical, Shanghai Hansoh Biomedical patent RET inhibitors

Dec. 7, 2020

Ascentawits Pharmaceuticals discovers AKR1C3-activatable DNA alkylating drugs

Dec. 7, 2020

New MAPK 1 inhibitors identified at Medshine Discovery

Dec. 7, 2020

Phase III study of masitinib in first-line pancreatic cancer with pain shows survival increase

Dec. 4, 2020

Henan Zhiwei Biomedicine, Henan Normal University present new BTK inhibitors

Dec. 4, 2020

New EGFR inhibitors discovered at Zhejiang University

Dec. 4, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...